Molecular biology of bladder cancer: prognostic and clinical implications.
The role of various molecular determinants involved in the genesis, progression, and outcome of bladder cancer has been the focus of investigations for the past 2 decades. Increasingly, the analysis of the interplay between these molecular factors is taking center stage. We review herein the studies examining the effects of deregulation of the various molecules implicated in the cell cycle, apoptosis, and angiogenesis pathways and analyze the central role of p53 in regulating these pathways. Technological advancements enable detection and quantification of gene transcripts and protein products, helping us move toward achieving the goal of establishing diagnostic, prognostic, and therapeutic marker panels. Recent studies have therefore focused on multiple-marker analyses to generate informative panels that can have greater clinical value for bladder cancer management. The use of molecular marker panels can provide a more objective alternative to clinical parameters for diagnosis and treatment decisions. Clinical trials aimed at treating urothelial carcinoma based on a patient's molecular profile can be predicted to empower clinicians to personalize patient management through increased therapeutic efficacy.
Mitra
Anirban P
AP
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
Lin
Henry
H
Datar
Ram H
RH
Cote
Richard J
RJ
D051017:Apoptosis Regulatory Proteins / Q000502:physiology*; D018797:Cell Cycle Proteins / Q000502:physiology*; D016158:Genes, p53 / Q000502:physiology*; D005819:Genetic Markers; D006801:Humans; D009389:Neovascularization, Pathologic / Q000235:genetics*; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy
D051017:Apoptosis Regulatory Proteins; D018797:Cell Cycle Proteins; D005819:Genetic Markers